[Treatment of hypertensive hyperuricemic patients with a new beta blocker-diuretic combination].
The antihypertensive activity of two fixed beta-blocker combinations was compared in a randomized double-blind study. 18 patients with degree I or II hypertension and hyperuricaemia were treated with a once daily dose for 4 weeks. 9 patients received 200 mg celiprolol. HCl +25 mg chlorthalidone, and 9 patients were treated with 100 mg atenolol + 25 mg chlorthalidone. Both substances produced a similar reduction in blood pressure and heart rate. There was a significant rise in the serum uric acid level in both treatment groups.
D000328:Adult; D000368:Aged; D001262:Atenolol / Q000627:therapeutic use*; D017272:Celiprolol; D002752:Chlorthalidone / Q000627:therapeutic use*; D004338:Drug Combinations; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
D004338:Drug Combinations; D011412:Propanolamines; D014527:Uric Acid; D001262:Atenolol; D017272:Celiprolol; D002752:Chlorthalidone
Behandlung mit einer neuen Betablocker-Diuretikum-Kombination bei hypertonen hyperurikämischen Patienten.